Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI116988

Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation.

P Holvoet, G Perez, H Bernar, E Brouwers, B Vanloo, M Rosseneu, and D Collen

Center for Molecular and Vascular Biology, University of Leuven, Belgium.

Find articles by Holvoet, P. in: PubMed | Google Scholar

Center for Molecular and Vascular Biology, University of Leuven, Belgium.

Find articles by Perez, G. in: PubMed | Google Scholar

Center for Molecular and Vascular Biology, University of Leuven, Belgium.

Find articles by Bernar, H. in: PubMed | Google Scholar

Center for Molecular and Vascular Biology, University of Leuven, Belgium.

Find articles by Brouwers, E. in: PubMed | Google Scholar

Center for Molecular and Vascular Biology, University of Leuven, Belgium.

Find articles by Vanloo, B. in: PubMed | Google Scholar

Center for Molecular and Vascular Biology, University of Leuven, Belgium.

Find articles by Rosseneu, M. in: PubMed | Google Scholar

Center for Molecular and Vascular Biology, University of Leuven, Belgium.

Find articles by Collen, D. in: PubMed | Google Scholar

Published January 1, 1994 - More info

Published in Volume 93, Issue 1 on January 1, 1994
J Clin Invest. 1994;93(1):89–98. https://doi.org/10.1172/JCI116988.
© 1994 The American Society for Clinical Investigation
Published January 1, 1994 - Version history
View PDF
Abstract

mAb4E4, a murine monoclonal antibody that is specific for acetylated LDL and malondialdehyde-treated LDL, binds specifically to modified LDL present in human atherosclerotic lesions. It is directed against an epitope that is poorly exposed in delipidated and solubilized apolipoprotein B-100 from modified LDL. mAb4E4, as well as its F(ab')2 and Fab fragments, enhanced the uptake of both acetylated LDL and malondialdehyde-treated LDL by THP-1-derived macrophages resulting in a sixfold increase of cytoplasmic cholesteryl ester levels. The increased uptake of modified LDL/mAb4E4 complexes did not occur via the Fc receptor and did not depend on aggregation of modified LDL particles. However, their uptake was inhibited by blocking the scavenger receptors with fucoidin or by downregulation of receptor expression with endotoxins or interferon-gamma, indicating that their uptake is mediated via these receptors. Thus, generation of autoimmune antibodies against modified LDL and subsequent endocytosis of soluble modified LDL/antibody complexes via scavenger receptors may enhance foam cell generation. This mechanism may contribute to the progression of atherosclerotic lesions.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 89
page 89
icon of scanned page 90
page 90
icon of scanned page 91
page 91
icon of scanned page 92
page 92
icon of scanned page 93
page 93
icon of scanned page 94
page 94
icon of scanned page 95
page 95
icon of scanned page 96
page 96
icon of scanned page 97
page 97
icon of scanned page 98
page 98
Version history
  • Version 1 (January 1, 1994): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts